Introduction: A Critical Lifeline for Providers and Patients

On November 15, 2024, the DEA and HHS announced an extension of telehealth prescribing flexibilities for controlled substances, now effective through December 31, 2025. This temporary rule is the third extension of a set of proposed rules that afforded providers significant flexibility in prescribing controlled substances. The rule allows prescribers to continue prescribing Schedule II-V medications remotely without requiring an in-person evaluation, a practice first introduced during the COVID-19 public health emergency (PHE). With these protections originally set to expire at the end of 2024, the extension offers much-needed continuity while the public awaits permanent telehealth rules to be finalized. For providers, the announcement is a reminder to stay informed, maintain compliance, and prepare for potential changes ahead.

Telehealth Prescribing Flexibilities: A Pandemic Response That Endures

When the COVID-19 PHE began in 2020, telehealth prescribing became essential for ensuring continuity of care. The Ryan Haight Act, enacted in 2008, traditionally required providers to conduct an in-person evaluation before prescribing controlled substances. As the pandemic revealed the need for more flexible approaches, the DEA announced that it would temporarily waive this requirement for DEA-registered prescribers. The waiver allowed providers to issue prescriptions for Schedule II-V controlled substances under certain conditions. Many providers took advantage of this waiver, which expanded access to essential medications for mental health disorders, chronic pain, and opioid use disorder.

In February 2023, the DEA issued two proposed rules (the Telemedicine Controlled Substance Proposed Rule and the Telemedicine Buprenorphine Proposed Rule) to address the use of telemedicine in issuing controlled substances following the end of the COVID-19 PHE. While the rules imposed more restrictions on telehealth prescribing, they afforded prescribers time to adjust to a post-pandemic world and a changing regulatory landscape.

Prior to the latest extension, the agency issued temporary rules in May and October 2023, allowing providers to continue prescribing controlled substances via telehealth platforms through the end of 2024. The expansion has been particularly vital for rural populations and those with limited access to in-person care. The latest extension highlights the DEA and HHS’s commitment to preserving access while addressing the complexities of regulating telemedicine practices.

The New Rule: Key Details Providers Should Know

The latest temporary rule mirrors the DEA’s prior extensions, allowing providers to continue prescribing controlled medications through both audio-video and audio-only systems through the end of 2025 without requiring in-person visits. The rule also leaves in place various conditions for these prescriptions, which must be issued by DEA-registered prescribers for legitimate medical purposes using DEA and HIPAA-compliant telehealth platforms. The extension signals a continuation of the status quo, preserving access to care for patients who have relied on telemedicine services for the past few years.

The DEA and HHS aim to finalize permanent regulations by the end of 2025, though it remains to be seen if the incoming administration could affect this timeline. Until then, providers should operate within the extended flexibilities, remaining mindful of both federal and state-specific requirements.

Implications for Providers: What to Prioritize

For prescribing providers, this extension offers a chance to refine telehealth practices and ensure compliance. Robust documentation remains critical. Telehealth records should clearly establish the medical necessity for prescribing controlled substances, particularly when no prior in-person evaluation exists. Providers should also verify patient identity and ensure that all telehealth platforms used in their practices meet DEA and HIPAA security standards.

Practices operating across state lines must remain vigilant to ensure their practice is compliant with each state’s requirements. State telehealth regulations vary widely, and understanding these nuances is essential for avoiding legal complications. This extension also presents an opportunity for providers to prepare for future regulatory changes, such as stricter guidelines on initial patient evaluations or technology requirements.

Patient Impact: Bridging the Gap in Care

The extension is not just a technical adjustment—it’s a lifeline for millions of patients. Telehealth prescribing has transformed access to care, particularly for those in rural or underserved communities. Without these flexibilities, patients managing opioid dependency, chronic pain, or mental health disorders face significant barriers to obtaining needed treatment. The continuation of audio-only options ensures that even patients with limited internet access can maintain continuity of care.

The importance of this decision extends beyond convenience. It preserves a model of care that has demonstrated its value in reducing stigma, improving treatment adherence, and expanding access for vulnerable populations.

Conclusion: A Measured Step Toward Permanent Solutions

The DEA and HHS’s extension of telehealth prescribing flexibilities reflects an ongoing commitment to balancing accessibility with regulatory oversight. For providers, the rule is both a reprieve and a call to action—an opportunity to strengthen existing telehealth practices and ensure alignment with current and future standards. As the healthcare system evolves, telehealth prescribing is poised to remain a vital component of patient care, particularly for controlled substances.

This extension is a bridge to a new era of telemedicine. By focusing on compliance, maintaining meticulous records, and staying informed about potential regulatory changes, providers can navigate this transitional period effectively.

For more information on the DEA’s extension of COVID-era prescribing flexibilities, call our team today.

‍